ARRS: How to manage the side effects of radiopharmaceuticals
AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. It can be life-threatening, Major said, and the nursing team may need to know what to do.
Let's personalize your content